Schizophrenia Clinical Trials in Chicago, IL

About Schizophrenia Clinical Trials in Chicago

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 12 schizophrenia clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 2,495 participants. Research is being sponsored by University of Texas Southwestern Medical Center, LB Pharmaceuticals Inc., Washington University School of Medicine and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.